Bicycle Therapeutics Limited (NASDAQ:BCYC) Sees Large Growth in Short Interest

berry sinaga

Bicycle Therapeutics Limited (NASDAQ:BCYC) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 188,200 shares, a growth of 22.0% from the August 31st total of 154,300 shares. Currently, 1.3% of the shares of the company are short sold. […]

Bicycle Therapeutics Limited (NASDAQ:BCYC) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 188,200 shares, a growth of 22.0% from the August 31st total of 154,300 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average trading volume of 74,300 shares, the short-interest ratio is presently 2.5 days.

In related news, major shareholder Plc Glaxosmithkline sold 1,597 shares of the company’s stock in a transaction dated Tuesday, July 14th. The shares were sold at an average price of $19.27, for a total value of $30,774.19. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 26.30% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its holdings in shares of Bicycle Therapeutics by 62.2% in the first quarter. Victory Capital Management Inc. now owns 219,734 shares of the company’s stock worth $3,213,000 after acquiring an additional 84,238 shares during the last quarter. Morgan Stanley raised its holdings in Bicycle Therapeutics by 32,450.0% in the 1st quarter. Morgan Stanley now owns 3,255 shares of the company’s stock valued at $44,000 after buying an additional 3,245 shares during the last quarter. Squarepoint Ops LLC bought a new position in Bicycle Therapeutics in the 1st quarter valued at approximately $179,000. FMR LLC bought a new position in Bicycle Therapeutics in the 2nd quarter valued at approximately $3,277,000. Finally, UBS Group AG bought a new position in Bicycle Therapeutics in the 2nd quarter valued at approximately $36,000. 35.54% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently weighed in on BCYC. Oppenheimer reaffirmed a “buy” rating and set a $27.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday, September 22nd. BidaskClub cut shares of Bicycle Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 27th. ValuEngine cut shares of Bicycle Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, August 6th. Finally, Canaccord Genuity upped their price objective on shares of Bicycle Therapeutics from $23.50 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Bicycle Therapeutics presently has an average rating of “Buy” and an average target price of $22.40.

BCYC stock opened at $19.50 on Friday. Bicycle Therapeutics has a 12 month low of $7.50 and a 12 month high of $21.59. The firm has a 50-day moving average price of $18.16 and a 200-day moving average price of $16.09.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Wednesday, August 5th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.19). The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.11 million. Bicycle Therapeutics had a negative return on equity of 43.74% and a negative net margin of 434.29%. As a group, analysts anticipate that Bicycle Therapeutics will post -2.38 EPS for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Read More: What is the market perform rating?

Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article

Next Post

Fuel reduction is possible in an AV world

Rizzoni and his team achieved a major step toward such an ecosystem with their NextCar project, assigned and funded by a division of the U.S. Department of Energy. The team entered the project with the high-risk, high potential goals of improving next-generation automated functions in passenger and commercial vehicles—and perhaps […]

Subscribe US Now